Germany’s laboratory and process equipment provider Sartorius AG (SDMHF.PK) Tuesday reported a higher profit for its full year, reflecting double-digit sales growth as well as improved margins. The company expects further growth in earnings for 2013.
For 2013, the company expects sales revenue at constant currencies to increase by about 6 to 9 percent. Without considering any currency effects, operating EBITA margin at Group level is expected to increase to about 16.5 percent.
The company said the performance of its Bioprocess Solutions division, that primarily specializes in single-use products for pharmaceutical drug manufacture, was “highly successfully”. In addition, initial consolidation of Biohit Liquid Handling business led to a significant growth for its Lab Products & Services division.
Joachim Kreuzburg, CEO of the company said, “Our bioprocess business has performed excellently over the last years. In 2012, we grew again at double-digit rates, more strongly than the market and also at a slightly faster pace than we ourselves expected. Especially in the USA, we have gained market share.”
Announcing its preliminary figures for 2012, the company said its net profit increased to 62.9 million euros or 3.68 euros per share from 52.8 million euros or 3.09 euros per share in the previous year.
Earnings per preference share totaled 3.70 euros, compared to 3.11 euros per share in 2011.
Operating earnings, or underlying EBITA climbed 20.3 percent to 135.0 million euros and EBITA margin improved to 16.0 percent from 15.3 percent a year ago.
Consolidated sales revenue for the year grew 15.4 percent to 845.7 million euros. At constant currencies, sales were up 11.7 percent.
On Frankfurt’s Xetra, Sartorius shares closed Monday’s regular trading at 70.11 euros, up 0.16 percent.
To receive FREE breaking news email alerts for Sartorius AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News